Rapport Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Rapport Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $57.1. The average 1-year stock price forecast is 55.67% higher than the current stock price, while the lowest is $40 (+9.05%) and the highest is $80 (+118.10%).

Price Target: $57.1 (+55.67%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$40	$57.1	$56	$80
Change	+9.05%	+55.67%	+52.67%	+118.10%

Analyst Ratings

The average analyst rating for Rapport Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	9	9	10	10	10
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	10	10	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kambiz Yazdi BTIG	BTIG	Buy Maintains $65	Buy	Maintains	$65	+77.21%	Jun 2, 2026
Danielle Brill Truist Financial	Truist Financial	Buy Maintains $44 → $56	Buy	Maintains	$44 → $56	+52.67%	May 18, 2026
Paul Matteis Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $56	Buy	Maintains	$56	+52.67%	May 12, 2026
Justin Walsh JonesTrading	JonesTrading	Buy Reiterates $50	Buy	Reiterates	$50	+36.31%	May 7, 2026
Joseph Thome TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

20.00M

Revenue Next Year

n/a

from 20.00M

-100.00%

from 20.00M

EPS This Year

-3.47

from -2.86

EPS Next Year

-4.47

from -3.47

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	20.00M
Operating Income	-5.85M	-36.18M	-83.06M	-125.10M	-175.10M
Net Income	-11.62M	-34.79M	-78.31M	-111.48M	-166.41M
EPS	-	-	-	-2.86	-3.47
Free Cash Flow	-	-17.43M	-44.47M	-54.17M	-55.34M
No. Analysts	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	20.0M
Avg	20.0M
Low	20.0M

Revenue Growth

Revenue Growth	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-3.00
Avg	-3.47
Low	-3.67

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-